Psyence Biomedical Ltd. (NASDAQ:PBM – Get Free Report)’s share price dropped 11.3% during trading on Tuesday. The company traded as low as $2.51 and last traded at $2.51. 65,336 shares were traded during trading, an increase of 22% from the average daily volume of 53,460 shares. The stock had previously closed at $2.83.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Psyence Biomedical in a research note on Thursday, October 15th. Wall Street Zen upgraded shares of Psyence Biomedical to a “hold” rating in a report on Saturday, October 3rd. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.
Check Out Our Latest Report on PBM
Psyence Biomedical Stock Down 11.3%
About Psyence Biomedical
Psyence Biomedical Ltd. is a clinical-stage biopharmaceutical company developing nature-derived psychedelic treatments for mental health and palliative care. Its research focuses on psilocybin, a psychedelic compound, for potential use in supervised therapeutic settings. The company’s lead candidate, PEX010, is a naturally derived psilocybin product being studied for adjustment disorder in people receiving palliative care. Psyence Biomedical’s work centers on clinical development and evaluating the safety and potential therapeutic effects of this treatment.
Further Reading
- Five stocks we like better than Psyence Biomedical
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Psyence Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psyence Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
